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294Objective: This trial aimed to determine whether intraoperative graft assessment with criteria for graft revision
would decrease the proportion of patients with 1 or more graft occlusions or stenoses or major adverse cardiac
events 1 year after coronary artery bypass grafting.
Methods: A single-center, randomized, single-blinded, controlled clinical trial was designed. Patients were
randomized to either of 2 groups: intraoperative graft patency assessment using indocyanine-green fluorescent
angiography and transit-time flowmetry, with graft revision according to a priori criteria (imaging group), or stan-
dard intraoperative management (control group). Patients underwent follow-up angiography at 1 year.
Results: Between September 2005 and August 2008, 156 patients undergoing isolated coronary bypass grafting
were enrolled (imaging, n ¼ 78; control, n ¼ 78). Demographic and angiographic characteristics were similar
between groups. Operative, crossclamp, and cardiopulmonary bypass times were all nonsignificantly longer in
the imaging arm. The number of grafts per patients was similar (imaging, 3.0  0.7; control, 3.0  0.7). The
frequency of major adverse cardiac events (death, myocardial infarction, repeat revascularization) was not differ-
ent between groups at 1 year postoperatively (imaging, 7.7%; control, 7.7%). One-year angiography was per-
formed in 107 patients (imaging, 55 patients/160 grafts; control, 52 patients/152 grafts). The proportion of
patients with 1 graft occlusion or more was comparable in the imaging (30.9%) and control (28.9%) groups
(relative risk [95% confidence interval], 1.1 [0.6–1.9]; P ¼ .82), as were other graft patency end points. The
incidence of saphenous vein graft occlusion was high in both groups.
Conclusions: Routine intraoperative graft assessment is safe but does not lead to a marked reduction in graft
occlusion 1-year after bypass grafting. The incidence of saphenous vein graft failure remains high despite
contemporary practice and routine intraoperative graft surveillance. (J Thorac Cardiovasc Surg 2010;139:294-301)Supplemental material is available online.The success of coronary artery bypass graft (CABG) surgery
is contingent on using durable conduits to construct quality
anastomoses onto appropriate target coronary vessels. Med-
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The Journal of Thoracic and Cardiovascular SurgDespite the highly favorable outcomes of CABG, a signif-
icant number of patients experience early graft failure.
Historical and contemporary angiographic studies have
demonstrated up to 15% of saphenous vein grafts and 8%
of left internal thoracic artery grafts are occluded 1 week
after CABG.2,5-8 One postulate is that this is predominantly
a result of surgical/technical problems that may be repairable
at the time of the operation, if identified. Poor graft patency
has been clearly correlated with markedly increased 30-day
and late mortality.9
Tools for intraoperative patency assessment are widely de-
scribed in the literature. Indocyanine green (ICG) fluoroscopy
and transit-time ultrasound flowmetry (TTF) are validated and
easy-to-use means of identifying graft errors intraopera-
tively.10-14 However, they pose potential risks to the patient
by prolonging crossclamp and cardiopulmonary bypass
(CPB) times, and they theoretically could lead to poorer anas-
tomosis quality and patency by inappropriate revision.
The primary objective of this study was to assess whether
a strategy of intraoperative patency assessment and graft
revision can decrease the rate of graft occlusions, significant
stenosis, and/or major adverse clinical events (MACE) at 1
year after CABG. This is the first contemporary, random-
ized, controlled clinical trial to answer this question, whichery c February 2010
Abbreviations and Acronyms
CABG ¼ coronary artery bypass graft
CPB ¼ cardiopulmonary bypass
GRIIP trial ¼ Graft Imaging to Improve Patency
trial
ICG ¼ indocyanine green
MACE ¼ major adverse clinical event
TTF ¼ transit-time ultrasound flowmetry
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Dis of undeniable relevance to improving outcomes and
applying quality assurance to the contemporary and future
practice of CABG surgery.METHODS
The study was approved by the institutional research ethics board and
informed patient consent was acquired. The study design was a single-
center, randomized, single-blinded, controlled clinical trial (ClinicalTrials.
gov Identifier NCT00187421).
Patient Population
Eligibility criteria included the following: age older than 18 years; elec-
tive or emergency isolated, primary CABG with or without CPB; and left
ventricular ejection fraction greater than 20%. Exclusion criteria included
the following: those with contraindications to receiving intraoperative
ICG dye (iodine allergy, severe liver disease affecting ICG excretion), con-
traindications to follow-up angiography (chronic renal failure [creatinine>
180 mmol/L], severe peripheral vascular disease, coagulopathy, or obliga-
tory use of anticoagulants), or geographically inaccessible to follow-up.
Study Design and Randomization
Patients were randomized to a control or experimental (imaging) group
in a 1:1 allocation ratio. Control patients had intraoperative assessment of
graft patency based on clinical judgment of the attending surgeon using
criteria including probe patency, the ease of graft injection after completion
of the distal anastomosis, appearance and palpation of the completed graft,
the electrocardiogram, wall motion according to transesophageal echocardi-
ography, and hemodynamic stability. The experimental group had intrao-
perative graft assessment using fluorescence angiography (Novadaq SPY
ICG angiography system; Novadaq Technologies, Toronto, Ontario,
Canada) and TTF (Medtronic MediStim flowmeter, Medtronic, Inc,
Newport, Calif), with a strategy of graft revision based on a priori criteria,
in addition to clinical judgment.
A priori criteria for graft revision in the imaging group were any one of
the following ICG fluoroscopy findings: (1) occluded graft (no distal vessel
opacification seen), (2) greater than 50% stenosis by visual assessment of
either the graft body or the proximal or distal anastomosis site, or (3)
a stenosis of more than 50% in the native vessel within the first 1 cm distal
to the anastomosis. Grafts were also required to be revised if two of the
following three TTF findings were found at intraoperative graft assessment:
(1) a pulsatility index (resistance) greater than 5, (2) a diastolic flow fraction
less than 50%, and/or (3) mean flow less than 10 mL/min. If either ICG or
TTF criteria were met, grafts had to be revised.
Randomization was revealed after the sternotomy was performed and the
operative strategy finalized, namely, the choice of bypass conduits and the
use of CPB (on-pump vs off-pump). Randomization was via sealed enve-
lope allocation in blocks of 4 to 6. Crossovers were allowed; final analysis
was performed on an intent-to-treat basis.The Journal of Thoracic and CaStudy Procedures and Follow-up
Intraoperatively, in both groups, distal anastomoses were allowed to be
instrumented using probes or intracoronary shunts as per surgeon routine.
Intraoperative ICG angiography was performed with the Novadaq SPY sys-
tem as per a defined protocol, by experienced users.10,11 For on-pump cases,
our technique was to hand inject free grafts after the distal anastomosis was
constructed, perform CPB pump (arterial line) injections for in situ internal
thoracic artery fluoroscopic assessment, and inject into the central venous
line for proximal anastomosis assessment, after separation from CPB. For
off-pump cases, we performed hand injections of the distal anastomoses
of free grafts and injection into the central venous line for in situ grafts
and proximal anastomoses.
TTF was performed with the MediStim TTF system.12-14 In on-pump
cases, TTF measurements were performed after patients had been weaned
from CPB and achieved stable heart rhythm and hemodynamics. Appropriate
sized probes (2–4mm)were used andmeasurements deemed appropriate once
adequate (>50%) contact was determined by the acoustic coupling indicator.
Postoperative management was standardized for both groups. All
patients received aspirin (or other antiplatelet therapy if aspirin intolerant)
within 6 hours postoperatively. All other medications were prescribed as
clinically indicated, including the use of statins, beta-blockers, calcium-
channel blockers for patients receiving radial artery grafts, and angioten-
sin-converting enzyme inhibitors.
Patients had routine clinical assessments before discharge and at 3
months, 6 months, and 12 months after the operation. These included rou-
tine serial electrocardiograms, blood work, a clinical examination, and en-
quiries into any symptoms, hospitalizations, investigations, and
medication use.
Patients underwent angiography at approximately 1 year, either by con-
ventional radiography or 64-slice computed tomographic angiography
(which has been validated at our institution). Initially, the trial protocol
required conventional x-ray angiography at 4 to 12 weeks after CABG.
However, this was amended to include either x-ray angiography or less
invasive computed tomographic angiography, up to 1 year after CABG,
to improve patient compliance with follow-up angiography.
End Points
The primary end point compared the imaging group to the control group
with respect to the proportion of patients with 1 or more totally (100%)
occluded grafts at 1 year’s follow-up angiography. Secondary end points
compared the 2 groups regarding the proportion of patients with 1 or
more graft with a significant (50%–99%) stenosis, the proportion of
patients with graft occlusion or significant stenosis, as well as the incidence
of perioperative clinical events and MACE (death, myocardial infarction,
repeat revascularization, or percutaneous coronary intervention) at 30
days and 1 year. Grafts with diffuse narrowing (to<1 mm) were recorded
as ‘‘string signs.’’ Postoperative angiograms, serial electrocardiograms,
and clinical information were reviewed by a blinded Angiographic and
Clinical Endpoints Committee. Perioperative myocardial infarction was de-
fined as the presence of new or deeper Q waves on 2 or more contiguous
leads on the postoperative 12-lead electrocardiogram or a peak creatine
kinase MB greater than 70 mg/mL.15
Statistical Analysis
Continuous variables were reported as mean  standard deviation and
categorical variables as a frequency and proportion. All analyses were per-
formed on an intention-to-treat basis. The primary (ie, graft occlusion) and
secondary end points (ie,>50% stenosis and>50% stenosis or occlusion)
were evaluated on a patient level and were expressed with relative risks and
95% confidence intervals. Graft patency was also recorded per distal anas-
tomosis as an ancillary outcome. Statistical differences between groups
were determined by the c2 test and Fisher’s exact test when appropriate
and with a Wilcoxon rank sum test for differences in lengths of follow-
up. SAS version 9.1 (SAS, Inc, Cary, NC) was use to execute statisticalrdiovascular Surgery c Volume 139, Number 2 295
TABLE 1. Preoperative patient demographic and angiographic characteristics, by group (N ¼ 156)
Imaging group Control group
All patients
(n ¼ 78)
Patients with
angiography
(n ¼ 55)
All patients
(n ¼ 78)
Patients with
angiography
(n ¼ 52)
Age, y  SD 62.3  12.3 60.7  9.5 64.3  8.9 63.9  9.0
Female, n (%) 9 (11.5) 5 (9.1) 10 (12.8) 5 (9.6)
Diabetes, n (%) 24 (30.8) 13 (23.6) 25 (32.1) 16 (30.8)
Hypertension, n (%) 53 (67.9) 38 (69.1) 61 (78.2) 39 (75.0)
Hyperlipidemia, n (%) 69 (88.5) 52 (94.5) 73 (93.6) 44 (84.6)
Smoking history, n (%) 39 (50.0) 26 (47.3) 43 (55.1) 28 (53.8)
Family history, n (%) 32 (41.0%) 27 (49.1) 21 (26.9) 17 (32.7)
Previous MI, n (%) 28 (35.9) 21 (38.2) 27 (34.6) 16 (30.8)
LVEF<35%, n (%) 8 (10.3) 4 (7.3) 5 (6.4) 3 (5.8)
CCS class  III, n (%) 32 (41.0) 21 (38.2) 31 (39.7) 18 (34.6)
Preoperative creatinine
(mmol/L)  SD
90.0  21.5 86.8  17.6 87.1  17.2 88.4  18.5
Peripheral vascular
disease, n (%)
6 (7.7) 4 (7.3) 5 (6.4) 2 (3.8)
Previous PCI, n (%) 9 (11.5) 8 (14.5) 9 (11.5) 5 (9.6)
Nonelective surgery, n (%) 12 (15.4) 9 (16.4) 15 (19.2) 8 (15.4)
Left main disease, n (%) 10 (12.8) 4 (7.3) 15 (19.2%) 11 (21.2)
No. of diseased
vessels, 1/2/3, n (%)
6/25/47 (7.7/32.1/60.3) 6/15/34 (10.9/27.3/61.8) 4/21/53 (5.1/26.9/67.9) 2/16/34 (3.8/30.8/65.4)
SD, Standard deviation; MI, myocardial infarction; LVEF, left ventricular ejection fraction; CCS, Canadian Cardiovascular Society; PCI, percutaneous coronary intervention.
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rity of the data. All of us have read and agreed to the manuscript as written.RESULTS
Between September 2005 and August 2008, 156 patients
were enrolled into the Graft Imaging to Improve Patency
(GRIIP) trial: 78 were randomized to the imaging group
and 78 to the control group. Balance from randomization
is shown in Table 1.
Table 2 summarizes the operative characteristics of the
imaging versus control patients. The total number of grafts
constructed and grafts per patient were no different between
groups. Operative times (total, CPB, and crossclamp) were
longer in the imaging group; however, this difference was
not statistically significant.
Table 2 displays the adherence to the protocol in both the
imaging and control groups. There were 3 crossovers in the
control arm (3.4%), involving 8 grafts, which were assessed
using the experimental intervention (ICG and/or TTF) on the
basis of surgeon suspicion regarding graft anastomosis qual-
ity. None of these 8 grafts met the a priori criteria for graft
revision, yet 5 grafts were revised as per surgeon decision.
Conversely, in the imaging group, 8 (3.6%) of the total
234 grafts constructed met criteria for revision; however,
only 4 (1.7%) grafts (involving 4 different patients) were
revised (3 of which were from the 8 meeting revision criteria
and another 1 that was revised on the basis of surgeon pref-
erence [ICG and TTF were normal]). The unrevised 4 grafts296 The Journal of Thoracic and Cardiovascular Surg(protocol violations) were attributed to the surgeon’s judg-
ment that revision was unwarranted and unlikely to result
in a better outcome. A small proportion of patients in the im-
aging group received no intraoperative assessment (7 grafts,
3.0%, in 3 patients). This nonadherence to the protocol was
due to technical malfunctions related to imaging and transit-
time systems.Angiography End Points
Follow-up angiographic results are shown in Table 3. A
total of 107 patients received follow-up angiographic assess-
ment (x-ray angiography, 23; computed tomographic angi-
ography, 84). These comprised 55 patients in the imaging
group and similarly 52 patients in the control group, at
a mean follow-up of 12.1  10.5 months and 13.3  9.8
months after CABG, respectively (P ¼ .51). The preopera-
tive characteristics of the entire group and the patients who
underwent angiography were similar (Table 1). In addition,
there were no differences between the imaging and control
patients who completed follow-up angiography. The reasons
precluding follow-up angiography were as follows: death in
1 patient, late refusal in 30 patients, new contraindications to
research angiography in 14 patients, and lost to follow-up in
4 (all of whom had moved out the country).
Overall, 13.8% of all studied grafts (43/312) were
occluded. The primary study outcome, the proportion of
patients with 1 or more graft occlusions at 1 year afterery c February 2010
TABLE 2. Operative characteristic and intraoperative graft
assessment details using indocyanine-green fluoroscopy (ICG) and
transit-time flowmetry (TTF), by group (N ¼ 156)
Imaging group
(n ¼ 78)
Control group
(n ¼ 78)
Operative characteristics
Total No. of bypass grafts 234 233
No. of bypass grafts/
patient, mean  SD
3.0  0.7 3.0  0.7
Number of arterial grafts/
patient, mean  SD
1.4  0.6 1.4  0.5
LITA/RITA/RA grafts,
n (% of patients)
74/7/29 (94.8/9.0/37.2) 78/6/22 (100/7.7/28.2)
Off-pump, n (%) 7 (9.0) 5 (6.4)
Crossclamp time, min,
mean  SD
109  32 97  22
CPB time, min,
mean  SD
128  37 116  25
Total operating room time,
min, mean  SD
336  76 319  83
Intraoperative graft
assessment details
Grafts assessed with both
ICG and TTF, n (%)
170 (72.6) 6 (2.6)
Grafts only assessed with
ICG, n (%)
53 (22.6) 2 (0.9)
Grafts only assessed with
TTF, n (%)
4 (1.7) 0 (0)
Grafts not assessed with
ICG or TTF, n (%)
7 (3.0) 225 (96.6)
Grafts meeting revision
criteria, n (%)
8/234 (3.6) 0/8 (0)
Revised grafts, n (%) 4 (1.7) 5 (2.1)
SD, Standard deviation; LITA, left internal thoracic artery; RITA, right internal thoracic
artery; RA, radial artery; CPB, cardiopulmonary bypass.
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28.9%, relative risk [95% confidence intervals], 1.1
[0.6–1.9]; P¼ .82). Nor was any difference noted in our sec-
ondary angiographic outcomes of 1 or more significant ste-
noses (50%–99%), or any occlusion or significant stenosis,
between the 2 groups. Table 3 also demonstrated that the rate
of occlusion or stenosis was substantially higher in saphe-
nous vein grafts (49/159, 30.8%) than in arterial grafts (6/
153, 3.9%).
At approximately the 1-year angiographic assessment,
there were no occlusions of the left internal thoracic arteries
in the imaging group and 2 occlusions in the control group
(P ¼ .22); there were no right internal thoracic arteries
occluded in either group. Six string signs were noted on
1-year angiography in 6 patients in the imaging arm com-
pared with 2 string signs at follow-up angiography in the
control arm (both in the same patient). Stratified analysis
looking at time to follow-up angiography did not reveal
any differences in outcomes between the 2 groups.
Excluding grafts with criteria for revision (see subsequent
paragraph), intraoperative ICG angiography indicated thatThe Journal of Thoracic and Caall grafts assessed that were occluded on subsequent follow-
up angiography were patent intraoperatively. TTF also did
not distinguish between grafts that subsequently became
occluded and those that remained patent according to
mean flow (30.5  13.4 vs 33.9 22.7 mL/min), pulsatility
index (3.09  1.87 vs 3.12  3.11), or diastolic fraction
(61.2%  13.3% vs 65.5%  12.6%).Grafts Revised or Meeting Revision Criteria
Eight grafts in the imaging group met revision criteria
according to intraoperative ICG and/or TTF assessments.
In all these grafts, ICG fluorescence angiography showed
normal findings, but revision criteria were met for TTF
measures. Of the 8 total grafts that received intraoperative
assessment measures and met criteria for revision (1 left
internal thoracic artery, 1 radial artery, 6 saphenous vein
grafts), 3 were revised (1 radial artery, 2 saphenous vein
grafts). Six of these 8 grafts were studied postoperatively;
1 of 2 revised grafts was occluded whereas 3 of 4 nonrevised
grafts were patent.
Six grafts were either not imaged or did not meet revision
criteria but were revised on the basis of clinical criteria alone
(4 left internal thoracic artery grafts, 2 saphenous vein
grafts). Five of these 6 grafts were assessed postoperatively;
2 grafts (2 left internal thoracic arteries) were occluded (see
Appendix E1 online)Perioperative Outcomes and MACE
There were no differences in the incidence of periopera-
tive events or MACE at 1 year between the 2 groups
(Table 4). Concomitant medical management was similar
in the imaging and control patients at discharge and at
1 year after surgery (Table 5).DISCUSSION
The GRIIP trial aimed to determine whether intraopera-
tive graft assessment with graft revision criteria would result
in improved angiographic patency and clinical outcomes at 1
year after CABG surgery when compared with routine intra-
operative assessment without imaging or flow measurement
tools. The study demonstrated that routine intraoperative
graft assessment was safe and feasible but did not lead to
a significant reduction in the frequency of 1 or more graft
occlusions, stenoses, or MACEs at 1 year after CABG.
The GRIIP trial also showed that the incidence of 1-year
saphenous vein graft occlusion remains high, despite the
coexistent use of evidence-based care including antiplatelets
and statins in a very high proportion of patients. This obser-
vation is consistent with other contemporary studies, includ-
ing the PREVENT IV trial,3 a multicenter randomized trial
that enrolled 3014 patients after CABG between 2002 and
2003. The authors found 45% of all patients had 1 or
more saphenous vein graft occlusions. In fact, 25% of allrdiovascular Surgery c Volume 139, Number 2 297
TABLE 3. Angiographic patency results at 1 year, by group
Imaging group
(n ¼ 55)
Control group
(n ¼ 52) RR (95% CI) P value
Primary end point
Total No. of grafts 160 152
Graft occlusions, n (%) 24/160 (15.0) 19/152 (12.5) 1.2 (0.7–2.1) .52
Saphenous vein grafts 24/79 (30.4) 17/80 (21.3)
Arterial grafts 0/81 (0) 2/72 (2.8)
Patients with ±1 graft occlusion 17 (30.9) 15 (28.9) 1.1 (0.6–1.9) .82
Secondary end points
Grafts with>50% stenosis, n (%) 4/160 (2.5) 8/152 (5.3) 0.5 (0.1–1.5) .20
Saphenous vein grafts 1/79 (1.3) 7/80 (8.8)
Arterial grafts 3/81 (3.7) 1/72 (1.4)
Patients with 1 graft
with>50% stenosis
3 (5.5) 8 (15.4) 0.4 (0.1–1.3) .09
Grafts with a>50% stenosis or occlusion, n (%) 28/160 (17.5) 27/152 (17.8) 1.0 (0.6–1.6) .95
Saphenous vein grafts 25/79 (31.7) 24/80 (30.0)
Arterial grafts 3/81 (3.7) 3/72 (4.2)
Patients with 1 graft with>50% stenosis or occlusion 19 (34.6) 22 (42.3) 0.8 (0.5–1.3) .41
Bold face indicates primary and secondary angiographic end points. RR, Relative risk; CI, confidence interval.
TABLE 4. Postoperative clinical outcomes and MACE, by group
(N ¼ 156)
Imaging group
(n ¼ 78)
Control group
(n ¼ 78)
In-hospital outcomes
IABP, n (%) 1 (1.3) 0 (0)
Stroke, n (%) 0 (0) 1 (1.3)
CK-MB, mean (ng/mL)  SD 31.9  17.7 31.0  34.3
Chest reopening
for bleeding, n (%)
1 (1.3) 1 (1.3)
Postoperative length
of stay, mean
(d)  SD
8.5  7.5 7.6  4.4
MACE (1 y)
Death, n (%) 0 (0) 1 (1.3)
MI, n (%) 4 (5.1) 3 (3.8)
Repeat CABG, n (%) 0 (0) 1 (1.3)
Postoperative PCI, n (%) 2 (2.6) 1 (1.3)
Any MACE, n (%) 6 (7.7) 6 (7.7)
MACE, Major adverse clinical events; IABP, intra-aortic balloon pump; CK-MB, cre-
atinine kinase MB fraction; SD, standard deviation;MI,myocardial infarction; CABG,
coronary artery bypass graft surgery; PCI, percutaneous coronary intervention.
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similar to our study findings.
It is our contention that saphenous vein graft patency is
likely worse in the current era than that seen previously
related to the competing revascularization strategy of percu-
taneous coronary intervention. Percutaneous coronary inter-
vention has expanded its clinical indications. As a result,
patients referred for surgery have more diffuse, distal, small
vessels (<2 mm) and often calcific disease and/or stent fail-
ure. In a previous meta-analysis of antithrombotic graft pa-
tency trials, 588 (13.4%) of 4400 saphenous vein grafts
had occluded at the distal anastomosis in the actively treated
patients.16 Almost all of these studies had been completed in
the 1980s. The multicenter Radial Artery Patency Study17
compared the patency of the radial artery to the saphenous
vein graft in patients who served as their own controls,
recruited from 1996 through 2001. The results showed 8%
of radial artery bypass conduits and 13% of saphenous
vein graft conduits were occluded at 1-year angiography.
Concerns have been raised that saphenous vein graft occlu-
sion may be increased when veins are harvested by a mini-
mally invasive technique18 or by skeletonized saphenous
vein graft harvesting, by increasing trauma and endothelial
dysfunction. In this trial, saphenous vein grafts were
harvested under direct vision by an open technique. Future
innovations, pharmacologic or technical (eg, no-touch vein
harvesting),19 addressing improvement in saphenous vein
graft patency should be pursued.
Along with venous conduit predilection for failure, the
GRIIP trial results also indicate that 1-year graft failure
was likely related to fibrointimal hyperplasia as opposed to
early technical errors. In the group of patients who received
imaging, it was found that only 8 (3.6%) of a total of 225
grafts constructed had intraoperative flow assessment data298 The Journal of Thoracic and Cardiovascular Surgthat met revision criteria in the operating room. Even if all
these grafts were related to technical error, this estimate is
low in comparison with previous literature reporting early
(intraoperative or<1 week after CABG) technical graft fail-
ure up to 15%.1,6 Furthermore, the imaging modalities were
not sensitive considering the number of occluded or signif-
icantly stenosed grafts (28/160, 17.5%) seen at 1 year in
the imaging group. Nonetheless, despite poor patency,
MACE at 30 days and 1 year were low in each group, which
is consistent with other large, contemporary coronary
trials.3,17
Intraoperative graft assessment with ICG fluorescence
angiography has been validated with gold-standard x-rayery c February 2010
TABLE 5. Medications at discharge and 1 year postoperatively, by group
Medications at discharge Medications at 1 year
Imaging group
(n ¼ 78)
Control group
(n ¼ 77)
Imaging group
(n ¼ 78)
Control group
(n ¼ 78)
ACE inhibitors, n (%) 8 (10.3) 9 (11.7) 33 (42.3) 30 (39.0)
Calcium-channel blockers, n (%) 13 (16.7) 22 (28.6) 9 (11.5) 19 (24.7)
Beta-blockers, n (%) 59 (75.6) 65 (84.4) 49 (62.8) 56 (72.7)
ASA, n (%) 70 (89.7) 67 (87.0) 70 (89.7) 63 (81.8)
Anticoagulants, n (%) 8 (10.3) 7 (9.1) 4 (5.1) 5 (6.5)
Clopidogrel, n (%) 11 (14.1) 14 (18.2) 8 (10.3) 7 (9.1)
Lipid-lowering agents, n (%) 74 (94.9) 70 (90.9) 74 (94.9) 70 (90.9)
Diuretic, n (%) 4 (5.1) 1 (1.3) 10 (12.8) 9 (11.7)
Digoxin, n (%) 1 (1.3) 2 (2.6) 1 (1.3) 2 (2.6)
Amiodarone, n (%) 4 (5.1) 6 (7.8) 0 (0) 2 (2.6)
ACE, Angiotensin-converting enzyme; ASA, aspirin.
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angiographically depicting graft and native vessel disease
intraoperatively. It is easy to use, safe, and the GRIIP trial
demonstrated that it did not significantly affect operative,
CPB, or crossclamp times. This is consistent with the litera-
ture to date, which also shows ICG angiography to have
excellent inter-rater reliability for prompting graft revision
by identifying poor patency.10 A previous review at our cen-
ter looked at TTF, ICG, and x-ray angiography as the gold
standard performed within 1 week postoperatively for 139
bypass grafts.11 The sensitivity and specificity for ICG to
detect greater than 50% and 100% occlusions were 83%
and 100%, respectively. For TTF these were 24% and
98% for greater than 50% and 100% occlusions, respec-
tively. Balacumaraswami and associates20 concluded that
the combination of the emerging ICGmodality to the widely
available TTF resulted in improved confirmation of graft
patency and reduced inappropriate revisions, when
compared to TTF alone, when reviewing 266 grafts (in
100 patients) undergoing CABG.
However, the role of intraoperative angiography is
clearly influenced by surgeon input. In the GRIIP trial,
of the 8 (3.6%) grafts in the imaging group meeting revi-
sion criteria, half were not revised owing to surgeon
concern for greater technical challenge and poorer anasto-
mosis result with revision (protocol violations).
Conversely, in the control (no imaging) group, 5 grafts
were revised on the basis of surgeon discretion. It is also
instructive that 4 of the 7 revised grafts with angiographic
follow-up were patent, compared with 3 of 4 grafts that
met revision criteria but were not revised. It appears that
the results of intraoperative imaging should not be used
in isolation of clinical judgment.
We designed the study to look for large treatment effects,
inasmuch as we did not expect that the imaging strategy
would be widely adopted by surgeons if only small differ-
ences emerged. We had fairly broad inclusion/exclusion cri-
teria—conceivably the results may have differed if we hadThe Journal of Thoracic and Carestricted the study to higher risk patients. Furthermore,
the majority of patients underwent on-pump rather than
off-pump CABG surgery. Intraoperative patency assessment
is likely of greater necessity in off-pump CABG.We defined
the primary and secondary patency outcomes to be reported
on a per-patient basis, inasmuch as this is inherently more
conservative, and we believe is clinically more relevant
than reporting patency on a per–distal anastomosis basis.
No benefit was observed for the primary outcome; there
was a small, nonsignificant improvement in the imaging
group for the secondary end point occlusion or stenosis,
but this was not evident when distal anastomotic patency
was analyzed separately.
In conclusion, the GRIIP trial demonstrated that routine
intraoperative graft assessment with criteria for graft revi-
sion is safe and feasible. However, graft patency and clinical
outcomes at 1 year were not different when compared with
those in patients who did not receive intraoperative patency
assessment tools. Our trial suggests that intraoperative graft
patency assessment need not be used routinely, but only
when clinical suspicion of graft failure exists. The other prin-
cipal finding of our trial is that saphenous vein graft occlu-
sion remains an unresolved issue in the contemporary
practice of cardiac surgery.
We appreciate the efforts of Tony Chan, Nicholas Fountas, Jen-
nifer Ku, Michael Knightingale, and Davida Petroff, who assisted
in the database queries, chart reviews, and manuscript preparation.References
1. Goldman S, Copeland J, Moritz T, HendersonW, Zadina K, Ovitt T, et al. Starting
aspirin therapy after operation. Effects on early graft patency. Department of
Veterans Affairs Cooperative Study Group. Circulation. 1991;84:520-6.
2. FitzGibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coro-
nary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts
related to survival and reoperation in 1,388 patients during 25 years. J Am Coll
Cardiol. 1996;28:616-26.
3. Prevent IV Investigators. Efficacy and safety of edifoligide, an E2F transcription
factor decoy, for prevention of vein graft failure following coronary artery bypass
graft surgery. JAMA. 2005;294:2446-54.rdiovascular Surgery c Volume 139, Number 2 299
Acquired Cardiovascular Disease Singh et alA
C
D4. Kulik A, Brookhart A, Levin R, Ruel M, Solomon DH, Choudhry NK. Impact of
statin use on outcomes after coronary artery bypass graft surgery. Circulation.
2008;118:1785-92.
5. Berger PB, Alderman EL, Nadel A, Schaff HV. Frequency of early occlusion and
stenosis in a left internal mammary artery to left anterior descending artery bypass
graft after surgery through a median sternotomy on conventional bypass: bench-
mark for minimally invasive direct coronary artery bypass. Circulation. 1999;
100:2353-8.
6. Campeau L, Enjalbert M, Lesperance J, Vaislic C, Grondin CM, Bourassa MG.
Atherosclerosis and late closure of aortocoronary saphenous vein grafts: sequen-
tial angiographic studies at 2 weeks, 1 year, 5 to 7 years and 10 to 12 years after
surgery. Circulation. 1983;68(3 Pt 2):111-7.
7. Khan NE, De Souza A, Mister R, Flather M, Clague J, Davies S, et al. A random-
ized comparison of off-pump and on-pump multivessel coronary-artery bypass
surgery. N Engl J Med. 2004;350:21-8.
8. Puskas JD, Williams WH, Mahoney EM, Huber PR, Block PC, Duke PG, et al.
Off-pump vs conventional coronary artery bypass grafting: early and 1-year graft
patency, cost, and quality-of-life outcomes: a randomized trial. JAMA. 2004;291:
1841-9.
9. Fabricius AM, Gerber W, Hanke M, Garbade J, Autschbach R, Mohr FW. Early
angiographic control of perioperative ischemia after coronary artery bypass graft-
ing. Eur J Cardiothorac Surg. 2001;19:853-8.
10. Desai NDD, Miwa S, Kodama D, Cohen G, Christakis GT, Goldman BS, et al.
Improving quality of coronary bypass surgery with intraoperative angiography:
validation of a new technique. J Am Coll Cardiol. 2005;46:1521-5.
11. Desai NDD, Miwa S, Kodama D, Koyama T, Cohen G, Pellitier MP, et al. A
randomized comparison of intraoperative indocyanine green angiography and
transit-time flowmeasurement to detect technical errors in coronary bypass grafts.
J Thorac Cardiovasc Surg. 2006;132:585-94.
12. Canver CC, Dame NA. Ultrasonic assessment of internal thoracic artery graft flow
in the revascularized heart. Ann Thorac Surg. 1994;58:135-8.
13. Morota T, Duhaylongsod FG, BurfeindWR, Huang CT. Intraoperative evaluation
of coronary anastomosis by transit-time ultrasonic flowmeasurement. Ann Thorac
Surg. 2002;73:1446-50.
14. VanHimbergen DJ, Koenig SC, Jaber SF, Cerrito PB, Spence PA. A review of
transit-time flow measurement for assessing graft patency. Heart Surg Forum.
1999;2:226-9.
15. MEND-CABG II Investigators, Alexander JH, Emery RW Jr, Carrier M, Ellis SJ,
Mehta RH, et al. Efficacy and safety of pyridoxal 50-phosphate (MC-1) in high-
risk patients undergoing coronary artery bypass graft surgery: The MEND-
CABG II randomized clinical trial. JAMA. 2008;299:1777-87.
16. Fremes SE, Levinton C, Naylor CD, Chen E, Christakis GT, Goldman BS.
Optimal antithrombotic therapy following aortocoronary bypass: a meta-analysis.
Eur J Cardiothorac Surg. 1993;7:169-80.
17. Desai NDD, Cohen EA, Naylor CD, Fremes SE. A randomized comparison of
radial-artery and saphenous-vein coronary bypass grafts. N Engl J Med. 2004;
351:2302-9.
18. Rousou LJ, Taylor KB, Lu XG, Healey N, Crittenden MD, Khuri SF, et al. Saphe-
nous vein conduits harvested by endoscopic technique exhibit structural and
functional damage. Ann Thorac Surg. 2009;87:62-70.
19. Souza DS, Johansson B, Bojo¨ L, Karlsson R, Geijer H, Filbey D, et al. Harvesting
the saphenous vein with surrounding tissue for CABG provides long-term graft
patency comparable to the left internal thoracic artery: results of a randomized lon-
gitudinal trial. J Thorac Cardiovasc Surg. 2006;132:373-8.
20. Balacumaraswami L, Abu-Omar Y, Choudhary B, Pigott D, Taggart D. A
comparison of transit-time flowmetry and intraoperative fluorescence imaging
for assessing coronary artery bypass graft patency. J Thorac Cardiovasc Surg.
2005;130:315-20.Discussion
Dr Munir Boodhwani (Brussels, Belgium). Can you comment
on your power and sample size calculations? It is a smallish study
with negative results. What were your assumptions?
Dr Singh. In our original protocol and proposal for funding, we
hypothesized and calculated that roughly 200 patients would be
required per arm. This would achieve a power of 80%, given an300 The Journal of Thoracic and Cardiovascular Surgassumed event rate in the control group of 9% of grafts occluded,
with a relative risk reduction of 60%. Although we did not actually
recruit our intended sample, the event rate, occlusions in the control
group, was significantly higher at 30%. As well, the relative risk
reduction confidence interval included that which we had hypoth-
esized. On the basis of these parameters, it is reasonable to assume
a reasonable power and to make a meaningful conclusion from this
study.
Dr Boodhwani.Was the harvesting technique for the saphenous
vein similar in both groups?
Dr Singh. The method was standardized in both groups; it was
the conventional, open, nonminimally invasive harvesting tech-
nique.
Dr Jennifer Sue Lawton (St. Louis, Mo). You should be
commended on your low rate of graft revision despite imaging.
In St Louis, we do not have our hybrid operating room ready yet,
so the only thing I can really use for off-pump CABG is the flow
probe. It looked like part of your imaging was flow probe assess-
ment. Do you have any data to correlate your imaging with flow
probe information? In other words, would flow probe data alone
have prompted you to revise your grafts without the angiography
data?
Dr Singh. That is an excellent question. We used both tech-
niques in collaboration, because the evidence from our institution
has shown that the flow probe is more sensitive to complete occlu-
sions and the ICG technique was more sensitive to nonocclusive
disease.
When we looked at the grafts that were not revised, at 1-year
follow-up angiography, we looked at the mean pulsatility indexes,
the mean diastolic flow fractions, and the mean flows. Actually,
there was no difference in those that ultimately were occluded
and those that were not. However, most grafts that were revised
had more findings on the TTF than on the ICG. Thus there was
more of a predilection for revision with positive TTF findings.
Dr Beat H. Walpoth (Geneva, Switzerland). We pioneered the
TTF measurements 15 years ago. I think it is a nice study, but I am
not sure whether you can predict the flow at a 1-year follow-up
based on the initial flow. It would be marvelous, but it is so com-
plex; there are so many factors. However, on the other hand, you
had several revisions during surgery owing to bad flow or bad
visualization of the graft. Therefore, I think you cannot support
your conclusion, because your conclusion says that you should
measure flow only in high-risk patients and sporadically. The point
is, actually, that you should measure all grafts. This takes 1 minute
per graft, and if you measure all grafts you will not miss patients in
whom you should do a revision on site. That is how you will im-
prove your patency in the long run. Could you comment on these
aspects?
Dr Singh.What we have gleaned from our study is that there is
a need for improving quality assurance and that intraoperative tools
can identify potential errors and poorly constructed grafts. How-
ever, we also identified that perhaps there is still a role for clinical
judgment by surgeons as to what grafts are critical and at high risk
for failure, requiring revision, or what grafts should not be revised if
the outcome would be poorer patency owing to technical challenge,
but may not dramatically influence outcomes. As such, the collab-
oration of clinical judgment with objective evidence from intrao-
perative tools probably is what best leads to improving patencyery c February 2010
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Dand avoiding inappropriate graft revisions. As we have seen,
although it is hard to make a meaningful conclusion from a smaller
number, some of the grafts that met revision criteria, but were not
revised because of attending surgeon judgment, were still patent at
1-year follow-up angiography. I think we should not go full force to
say we should use it routinely; however, targeted use of clinical
judgment would probably be most ideal.
DrWalpoth. One follow-up question: If you had only one tech-
nique, which one would you prefer?
Dr Singh. Evidence from our institution, comparing ICG to TTF
to the gold standard, x-ray angiography, has shown that the sensi-
tivity and specificity of ICG for 50% to 90% stenoses and 100%
stenoses is superior to that of TTF. TTF has a sensitivity and spec-
ificity for nonocclusive disease much poorer than that of ICG. Thus
ICG might provide more data. Besides that, it is much more user
friendly and better provides an image that attending surgeons can
easily interpret as opposed to just interpreting numbers that are
provided by TTF.
Dr Keith Horvath (Bethesda, Md). This was an excellent
presentation of a difficult study to conduct. Some might assume
a conclusion from this trial is that hybrid operating rooms are not
really needed, because you have done a nice job showing that
imaging really did not have a significant impact at the time of
surgery. I am wondering whether that is a fair conclusion. My
second question is this: You have demonstrated that there are
many factors responsible for graft failure and that the technicalThe Journal of Thoracic and Caaspects at the time of the grafting, although they play a role, are
probably not as high of a factor in causing graft failure as we think.
From what you have been able to see in the grafts that failed, was
there any either qualitative or semiquantitative assessment of the
distal vessel that may have been the reason for those failures?
Did you learn anything in that regard? The extent of target vessel
disease is probably still a much more important factor in graft fail-
ure than the technical aspects of the operation.
Dr Singh. Thank you for those two questions. Your first ques-
tion concerned the role of imaging and queried the involvement
of evolution of hybrid operating rooms. I think there still is a role
for imaging, especially in the evolution of hybrid operating suites,
because in many situations what is being done is minimal access,
lower exposure, beating heart procedures. As such, these are the pa-
tients that are probably at high risk for poorer construction of distal
anastomoses and, as such, intraoperative angiography or imaging
should have a role.
With respect to your second question, we did note that the graft
revision rate was quite low and that the occlusions at 1 year obvi-
ously are multifactorial. Many things contribute to this, including
distal target characteristics. We have not looked at it in the present
study, but we will be looking at the data and comparing them. One
would anticipate that the degree of distal disease and the native
vessel characteristics, as has been shown in the literature, would
play a role in 1-year patency; however, given the randomization
of the study, we believe the impact should have been balanced.rdiovascular Surgery c Volume 139, Number 2 301
APPENDIX E1. Intraoperative and follow-up angiographic details of grafts revised or meeting revision criteria
Grafts
meeting
revision
criteria
or revised
(n ¼ 14)
ICG angiography TTF
Group
>50%
stenosis
TIMI
flow
ICG
result
Mean
flow
(mL/min)
Diastolic
flow
fraction
(%)
Pulsatility
index
TTF
result Revised? If no, why?
Postop
graft
status
LITA-LAD Imaging No III Normal 6.0 63 7.7 Abnormal No Poor distal
target, not
reparable;
small graft
Patent
SVG-D1 Imaging No III Normal 8.0 41 6.7 Abnormal No Poor distal
target, not
reparable
Patent
SVG-PIV Imaging No III Normal 43.0 32 9.4 Abnormal No Proximal
clearly
visualized
Patent,
with
mild
stenosis
SVG-OM Imaging No III Normal 18.0 20 5.9 Abnormal No Poor distal
target, not
reparable
Occluded
SVG-IM Imaging No III Normal 8.0 65 7.0 Abnormal No Poor distal
target, not
reparable
No
follow-up
angiography
RA-PIV Imaging No III Normal 8.0 6 18.8 Abnormal Yes Patent
SVG-OM1 Imaging No III Normal 9.5 30 16.4 Abnormal Yes Occluded
SVG-PL Imaging No III Normal 16.0 53 5.5 Abnormal Yes No
follow-up
angiography
SVG-OM1 Imaging No III Normal 25 85 3 Normal Yes Patent
LITA-OM1 Control No III Normal 24 68 2 Normal Yes Occluded
LITA-LAD Control NA NA NA NA NA NA NA Yes Patent
SVG-PIV Control NA NA NA NA NA NA NA Yes Patent
LITA-LAD Control NA NA NA NA NA NA NA Yes Occluded
LITA-LAD Control NA NA NA NA NA NA NA Yes No follow-up
angiography
ICG, indocyanine green; TTF, transit-time flowmetry; TIMI, Thrombolysis in Myocardial Infarction; LITA, left internal thoracic artery, LAD, left anterior descending artery; SVG,
saphenous vein graft; D, diagonal; PIV, ¼ posterior interventricular; OM, obtuse marginal; IM, intermediate; RA, radial artery; PL, posterolateral; NA, not applicable.
Acquired Cardiovascular Disease Singh et alA
C
D301.e1 The Journal of Thoracic and Cardiovascular Surgery c February 2010
